Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference28 articles.
1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Amer. 2000;6(Suppl 1):S55–7.
2. Clark JI, Morse MA, Wong MKK, McDermott DF, Kaufman HL, Daniels GA, et al. Durability of responses in patients with metastatic renal cell carcinoma treated with HD IL-2. JITC. 2015;3(Suppl 2):P225.
3. Alva A, Daniels GA, Wong MK, Kaufman H, Morse MA, McDermott DF, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65:1533–44.
4. Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, et al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother. 2016;65:941–9.
5. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:561–8.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献